Smoking in United States of America
In the United States of America, smoking is allowed but tobacco products should follow some regulations. Under these regulations, health warnings on tobacco packaging including cigarettes are mandatory, the minimum legal age for their sales is 21 years, and there are no federal legal restrictions on smoking in public places. While tobacco advertising is regulated, not all forms of their advertising are banned. An excise tax of 32.16% with a total taxation rate of 37.36% is applied on cigarettes. Cigarettes can legally be sold with authorised documents. They may also be purchased through vending machines as well as through online channels. Importing cigarettes for trade is allowed with an appropriate import license. Despite these control measures, prevalence data show that smoking remains an important public health issue in the United States. There were 39.8 million current smokers in the country in 2024. This represents an overall adult smoking prevalence of 14.1%, with higher prevalence among men (17.1%) than among women (11.1%). In comparison, the overall current smoking prevalence was 12.3% in 2022. The adult daily smoking prevalence was recorded to be 10.01% in 2020. Smoking-related mortality also remains significant in the country. In 2021, smoking resulted in 360,370 deaths, including 216,986 male deaths and 143,383 female deaths. This shows that smoking accounted for 10.38% of all deaths in the United States in 2021, with a higher rate among men (11.9%) than among women (8.7%).
Read articles from United States of America
October 15, 2026 by substack.com
Tobacco Risk Management: An Opportunity for Health Plans to Accelerate the Decline of Cigarette Smoking
Health insurers could play a much greater role in reducing smoking-related disease in the United States. Despite smoking cessation being among the most cost-effective medical interventions, fewer than half of smokers report receiving advice or assistance to quit.
Recent developments, including cheaper cessation medications, new clinical performance measures and growing evidence on safer nicotine alternatives, offer an opportunity to change that. Integrating tobacco harm reduction into health insurance programmes could improve patient outcomes while reducing long-term healthcare costs. The priority is not simply treating smoking-related disease, but investing in preventing it.
October 14, 2026 by clearingtheair.eu
INVESTIGATION: Who’s behind the anti-nicotine propaganda?
Anti-nicotine campaigns rarely present themselves as propaganda; they present themselves as protection. That is why scrutiny matters. Funding networks, advocacy strategies and institutional alliances can shape which evidence is amplified, which voices are excluded and how safer nicotine products are framed to the public. A serious public health debate should be able to follow the influence behind the message, especially when the result may be fewer options for adults trying to leave cigarettes behind.
October 14, 2026 by substack.com
THR Doesn’t Need Nicotine to Be Innocent
Tobacco harm reduction does not require nicotine to be innocent. It requires honesty about where the greatest harm comes from. Nicotine can cause dependence and should not be promoted casually, but cigarettes are deadly because they burn tobacco and expose users to toxic smoke. The case for safer nicotine products rests on reducing that exposure — not on pretending nicotine has no risks.
October 13, 2026 by daily-pouch.com
Media Watch: The WSJ Suggests Wellness Types Are Rehabilitating Nicotine
Nicotine entering wellness culture creates a communication challenge public health cannot ignore. A product may be smoke-free and far less harmful than cigarettes, but that does not make nicotine a lifestyle supplement or a harmless productivity tool. The clearest message is also the most nuanced: non-combustible nicotine can matter for smokers moving away from combustion, while non-users should not be encouraged to start. Risk communication needs to hold both truths at once.
October 12, 2026 by washingtonexaminer.com
The FDA’s $7 billion bureaucratic black box is fueling black markets
The FDA review backlog is not just an administrative problem; it shapes the market smokers actually face. Legal smoke-free products wait in uncertainty, while illicit and unapproved products move faster than the system designed to regulate them. That imbalance leaves adult smokers with fewer accountable options and gives the black market more space to grow. Product review should be rigorous, but it also has to be timely enough to support harm reduction in the real world.
October 09, 2026 by regulatorwatch.com
Rule Reset | FDA Signals Major Overhaul of PMTA Process | RegWatch
A reset of the FDA’s PMTA process is overdue if regulation is meant to guide the market rather than paralyse it. The current pathway has left many smoke-free products trapped in uncertainty while cigarettes remain legally available and illicit alternatives gain space. A better system should be rigorous, transparent and fast enough to distinguish responsible products from those that do not meet standards. Harm reduction depends on regulation that can make timely decisions, not one that delays safer options out of reach.
October 09, 2026 by pearlsandirritations.com
The growing gap between Australia’s policies on nicotine and reality
Australia’s nicotine policy is drifting further from the reality consumers are living in. Cigarettes remain legal, illicit tobacco is expanding, and many vapers are navigating workarounds, informal supply or rules that do not match how people actually quit smoking. That gap matters because policy cannot reduce harm effectively while pretending demand has disappeared or that restriction equals control. A better approach would start from real behaviour: keep people inside legal channels, make safer alternatives accessible, and measure success by fewer people smoking.
October 08, 2026 by 2firsts.com
From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
The FDA’s tobacco centre reworking its product review process matters because the current system has struggled to keep pace with the market it is supposed to regulate. Slow, uncertain pathways can leave responsible products waiting while cigarettes remain widely available and unapproved alternatives continue to circulate. A better review model should be faster without becoming weaker: clear standards, transparent decisions and evidence assessed according to relative risk. The goal should be a legal market where safer nicotine products are reviewed in time to help smokers move away from combustion.
October 08, 2026 by 2firsts.com
From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
The FDA’s tobacco centre reworking its product review process matters because the current system has struggled to keep pace with the market it is supposed to regulate. Slow, uncertain pathways can leave responsible products waiting while cigarettes remain widely available and unapproved alternatives continue to circulate. A better review model should be faster without becoming weaker: clear standards, transparent decisions and evidence assessed according to relative risk. The goal should be a legal market where safer nicotine products are reviewed in time to help smokers move away from combustion.
October 06, 2026 by gfn.tv
Is Regulation Ignoring the Evidence? The Challenge of Better Regulation | #GFN26 Science Lab
Better regulation begins with a simple discipline: look at the evidence before deciding what the policy should say. In tobacco and nicotine control, that means distinguishing between products, measuring actual exposure, and asking whether rules help smokers move away from combustion. Regulation that ignores evidence may still look decisive, but it can harden the wrong incentives and leave the greatest harms untouched. The challenge is not more regulation for its own sake — it is regulation that is proportionate, responsive and honest about risk.
- Page 1 of 170